Valuation: Flex Pharma Inc

Market Cap 2.63M 2.31M 2.15M 1.97M 3.7M 254M 3.77M 25.68M 10.01M 124M 9.87M 9.65M 431M P/E 2026 *
-0.38x
P/E 2027 * -0.26x
Enterprise Value 2.63M 2.31M 2.15M 1.97M 3.7M 254M 3.77M 25.68M 10.01M 124M 9.87M 9.65M 431M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.72%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
+22.97%+1,602.74% - - 2.63M
+1.23%+0.35%+51.62%+87.98% 55.92B
+5.09%+6.24%+63.15%+62.06% 56.67B
+0.25%+0.55%-19.67%-15.22% 23.28B
+0.72%-0.05%+3.84%+409.54% 23.28B
-0.31%+5.79%+31.06%-3.53% 20.54B
-0.37%+0.71%+31.36%-31.61% 17.78B
-0.86%+6.29%+33.32%+547.87% 15.9B
-2.54%-8.73%+164.11%+289.45% 14.64B
+1.22%-0.05%+22.58%+182.63% 13.99B
Average +2.74%+0.71%+42.37%+169.91% 26.89B
Weighted average by Cap. +1.38%+2.82%+43.56%+134.24%

Financials

2026 *2027 *
Net sales - -
Net income -10.7M -9.41M -8.74M -8.04M -15.08M -1.04B -15.35M -105M -40.78M -505M -40.17M -39.3M -1.75B -17.8M -15.66M -14.54M -13.38M -25.08M -1.72B -25.53M -174M -67.83M -841M -66.82M -65.38M -2.92B
Net Debt - -
Logo Flex Pharma Inc
Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence (AI) tools alongside high-speed synthesis techniques to design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
Employees
-